Peptide Side Effects: What Users Report and What the Evidence Shows
People report migraines, fatigue and hospital stays after unapproved peptides. What FDA and published case reports show, what is unknown, and what to do.
Read articleBlog
Perspectives on peptide science, research, and the evidence behind it.
Latest articles
Showing 1–9 of 26 articles
Compounded Semaglutide and Tirzepatide: FDA’s Plan to End Bulk Compounding Explained
FDA proposed keeping semaglutide, tirzepatide and liraglutide off the 503B bulks list. What it changes, what it does not, and where compounded GLP-1s stand.
Read article
FDA Panel Votes on BPC-157 and 6 Peptides: What Changed, What Didn't and What's Next
An FDA advisory panel backed BPC-157, TB-500 and 4 more peptides for compounding in July 2026. What the vote means, why FDA staff said no, and what comes next.
Read article
HHS Plan to Allow Temporary Sales of Unapproved Peptides: What We Know
A reported HHS plan would let pharmacies supply some unapproved peptides before FDA rules are final. What is confirmed, how it could work, and the risks.
Read article
“Research Use Only” Peptides: What the Label Really Means
Gray-market peptide sales have surged. What “research use only” means legally, what lab tests of online peptides found, and what a COA cannot show.
Read article
Orforglipron, Retatrutide and CagriSema: Where the Next Weight-Loss Drugs Stand
Orforglipron is approved, CagriSema awaits an FDA decision and a retatrutide filing is planned for 2027. Trial results, safety signals and what to watch.
Read article
GLP-1 Drugs Beyond Weight Loss: What’s Proven, Promising or Failed
Which GLP-1 uses are proven? Heart, kidney, liver and sleep apnea approvals, promising trials, and the Alzheimer’s and Parkinson’s results that failed.
Read article
How Regulatory Approval for Peptide Medicines Works
How a peptide drug gets approved: evidence, manufacturing quality, human trials and FDA or EU review, plus timelines and accelerated approval.
Read article
How to Spot Exaggerated Peptide Headlines
Check peptide headlines against original studies. Spot animal-to-human leaps, biomarker claims and misleading percentages using real research examples.
Read article